Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Blocklisting Interim Review

6 Oct 2014 15:58

RNS Number : 5739T
Hikma Pharmaceuticals Plc
06 October 2014
 



 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

Date: 6 October 2014

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From:

1 April 2014

To:

30 September 2014

Balance of unallotted securities under scheme(s) from previous return:

SOP: 967,900 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 378,360 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 38,200 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 356,752 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 929,700 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 21,608 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

 

 

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

967,900

Blocklisting return 01/04/2014

10/04/2014

0

8,500

959,400

25/04/2014

0

2,500

956,900

23/05/2014

0

1,000

955,900

12/06/2014

0

2,500

953,400

12/06/2014

0

1,700

951,700

21/08/2014

0

6,000

945,700

21/08/2014

0

7,500

938,200

12/09/2014

0

8,500

929,700

Blocklisting return 30/09/2014

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

400,050

Blocklisting return 01/04/2014

30/09/2014

-

-

400,050

Blocklisting return 01/10/2014

 

 

Management Incentive Plan ("MIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

378,360

Blocklisting return 01/04/14

18/05/2014

0

261,480

116,880

12/06/2014

0

11,619

105,261

13/06/2014

0

77,487

27,774

30/06/2014

0

741

27,033

07/08/2014

0

2,856

24,177

22/08/2014

0

794

23,383

04/09/2014

0

300

23,083

12/09/2014

0

1,475

21,608

 Blocklisting return 01/10/14

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMMGGDVVGDZM
Date   Source Headline
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM
21st Apr 20217:00 amRNSHikma resumes launch of generic Advair Diskus®
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.